A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
A study by UC Irvine found that the ePRO tool improved symptoms management for Hispanic and Asian patients undergoing chemotherapy, reducing pain, nausea, and vomiting. The tool, which uses real-time analytics and personalized treatment plans, also increased patient satisfaction.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
St. Jude researchers found that early surveillance after genetic predisposition discovery detects new, treatable tumors in 70% of cases. This approach can avoid chemotherapy and radiation, improving outcomes for children with cancer.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
The American Society for Radiation Oncology has released new guidelines for radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), recommending optimal dosing regimens to reduce acute and late effects. Concurrent chemotherapy with cisplatin is recommended for more advanced tumors or multiple lymph nodes.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
A study published in Frontiers in Oncology reveals breast cancer incidence has surged in oil-rich Gulf countries, with unique clinical and pathological features. The disease is attributed to a combination of menstrual cycle, hereditary factors, weaning children earlier than expected, hormonal treatment, obesity, and use of contraceptives.
Researchers found disparities in LGBTQ+ patient experiences, including discomfort with disclosure and lack of partner respect. International medical graduates face unconscious bias, limited opportunities, and financial stress, affecting their engagement with healthcare systems.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
The study found a 5.7% blood culture positive rate among eligible Hem-Onc patients, with 56% having an absolute neutrophil count greater than 500 µL at presentation. Gram-positive organisms were the most common isolates, highlighting the diversity of bloodstream infection causes in this patient population.
The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
Two new Review articles explore AI's application in early cancer detection, highlighting its potential to enhance diagnostic accuracy and improve treatment selection. The articles emphasize the need for a robust, multi-disciplinary approach to integrate AI into medicine.
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.
A Northwestern University study found ChatGPT's responses to radiation oncology patient questions were on par or exceeded professional society answers. The AI technology aims to empower patients before and after seeing physicians, while also reducing clinician burnout.
The DTEP model accurately predicts delayed treatment effects (DTE) in immuno-oncology trials, allowing for optimized trial designs. By tailoring trial lengths, the model enhances statistical power and accelerates immunotherapy development.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
Alex Jaeger, a Moffitt Cancer Center researcher, has received the Damon Runyon-Rachleff Innovation Award for his project on exploiting MHC-II antigen presentation in cancer. His goal is to develop advanced immunotherapeutic strategies by understanding how distinct patterns of antigen presentation trigger specific T-cell pathways.
A study published in JAMA Oncology found that MRI monitoring in women with BRCA1 mutations significantly reduces breast cancer mortality without the need for preventive mastectomy. The research included data from 2,488 women and showed a notable decrease in mortality rate among participants.
A new study found that many newly approved EU oncology drugs lack proof of added benefit, with over half recovering R&D costs within three years. This challenges the industry's claim that high drug prices are necessary to offset R&D expenses.
A study found that over half of cancer drugs approved through expedited pathways recover research and development costs within three years, despite lacking proof of added benefit. The researchers emphasize the need for better alignment between regulatory and reimbursement processes to promote effective drug development.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
A new study evaluates AI algorithms for autocontouring prior to radiotherapy in head and neck cancer. OpenAI's GPT-4-turbo demonstrated the best performance, while Llama-2 models underperformed. The study highlights the potential of generative AI to revolutionize radiation oncology education and practice.
A new machine learning model, COLOXIS, uses data from two NSABP clinical trials to predict which colon cancer patients will benefit from the addition of oxaliplatin. The model shows that patients with a signature-positive prediction can derive benefit from oxaliplatin, while those with a signature-negative prediction do not.
Dr. Eric Topol predicts that cancer screening will be transformed by AI in the next couple of years, with improved diagnosis accuracy and access to GPT support for doctors.
Liquid biopsies have the potential to monitor therapy success and predict tumor recurrence in high-risk neuroblastoma patients. The MONALISA project aims to establish liquid biopsies as a standard procedure for monitoring relapsed neuroblastoma, offering hope for improved personalized medicine.
A Phase 2B clinical trial, led by City of Hope, found that carvedilol may improve heart health markers and reduce the risk of heart failure in childhood cancer survivors. The study suggests that carvedilol could benefit long-term survivors and those who are highly adherent to the treatment.
Recent review highlights the potential of AGI in radiotherapy, enabling advanced auto-segmentation, tumor staging, and treatment planning. The fusion of vision data with large language models creates powerful multimodal models that elucidate nuanced clinical patterns.
A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.
A recent study published in The Lancet Oncology found that the risk of dying from cancer in some poorer districts of England is over 70% higher than in wealthier areas. The study used death records to estimate the risk of dying from various cancers in each district, highlighting significant inequalities in cancer mortality across diffe...
Bioethics researchers at Dana-Farber Cancer Institute warn that patient-facing AI can depersonalize care and erode relationships between patients and caregivers. The authors advocate for principles such as human dignity, patient autonomy, and regulatory oversight to ensure AI-driven healthcare is ethically sound and equitable.
The study found that precision oncology therapies require genomic biomarker screening for patient selection and have expanded over the years. The analysis showed a slow expansion in approvals from 1998 to 2017 and a rapid increase from 2017 to 2022, with 86 out of 198 approved drugs classified as precision oncology drugs.
Researchers from Memorial Sloan Kettering Cancer Center presented new findings on radiation-induced secondary cancers, a new guidance system for radiation therapy, and the consequences of insurance denials. The studies aimed to improve personalized treatment decisions for patients with rare cancer syndromes like Li-Fraumeni syndrome.
A novel liquid biopsy test identifies levels of circulating tumor DNA as a more precise measure of disease burden than the number of tumors themselves. Patients with lower levels of detectable ctDNA are more likely to benefit from radiation therapy.
A new set of criteria, RANO 2.0, has been proposed to improve the assessment of progression in glioma patients and accelerate the development of new treatments for brain tumors.
Cancer researchers at University of Cincinnati Cancer Center are exploring a new method called lattice therapy, which delivers higher doses to tumors and lower doses to surrounding tissues. The approach has shown promise in reducing treatment time and improving patient outcomes for head and neck, lung, and brain tumors.
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
The City of Hope will lead the way in integrating complementary therapies into cancer care, supporting holistic treatment for patients. The Cherng Family Center's research and clinical programs aim to advance evidence-based standards for integrative oncology, creating an international destination for its transformational work.
A secondary analysis of NRG Oncology-RTOG 0617 found IMRT reduced CTCAE grade ≥ 3 pneumonitis by 2-fold compared to 3D-CRT. The study suggests IMRT should be the radiation technique of choice for patients with locally advanced NSCLC.
The Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO) recommend mindfulness-based stress reduction, meditation, and mindful movement to treat anxiety and depression symptoms in cancer patients. These interventions have strong evidence supporting their benefits.
National guidelines recommend mindfulness meditation, yoga, and music therapy for cancer patients experiencing anxiety and depression. The guidelines are based on strong evidence from clinical studies, providing a comprehensive approach to managing these common side effects of cancer treatment.
The study identifies barriers to cancer treatment, including high drug costs and limited diagnostic infrastructure. It suggests strengthening the oncology workforce and training them on precision therapies to address this shortage.
A group of global oncologists and patient advocates argue that cancer care is driven by commercial interests, not patient needs. The 'Common Sense Oncology' movement aims to prioritize patient outcomes over profit-driven research and treatment development.
The Multidisciplinary Molecular Tumour Board (MTB) has been shown to improve treatment response rates for patients with advanced solid cancer, with 64% of patients benefiting from the MTB-guided approach. The board provides a systematic precision oncology strategy for treatment selection, combining expertise in multiple disciplines.
Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
A Vanderbilt University Medical Center study found potential savings of $661.8M (78.8%) if insurers purchased seven generic oncology drugs at MCCPDC prices, with total savings ranging from $228.1M to $2,154.5M.
The Montefiore Einstein Cancer Center received a $2.9 million grant to train physicians and scientists to conduct clinical and translational oncology research, focusing on addressing health inequities in the Bronx. Scholars will engage in interdisciplinary research projects with community outreach and engagement.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
At ASCO 2023, Sylvester Comprehensive Cancer Center experts are available to discuss a wide range of topics, including Sarcoma research, tumor agnostic precision oncology, and genitourinary cancers. The center's experts also share their perspectives on immunotherapy approaches for prostate cancer, breast cancer treatment, and melanoma.
The ATOM Coalition aims to improve cancer medicine availability and increase the capacity of lower-income countries to diagnose and manage cancer. The coalition prioritizes generic and biosimilar medicines for cancer treatments, targeting countries with high mortality rates.
A randomized clinical trial found that providing palliative care at the time of cancer surgery did not improve patient outcomes, including quality of life and survival. The study suggests that surgeons should not be reluctant to call for palliative care consultations based on fear of upsetting patients.
Researchers used human liver organoids to study fibrolamellar carcinoma, a rare childhood liver cancer. They found that different genetic mutations underlie different degrees of aggressiveness in the tumors, and uncovered the probable cell-of-origin as hepatocytes.
A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...
The NRG Oncology study found that stereotactic radiosurgery was not superior to conventional external beam radiotherapy in terms of pain response, and even showed worse pain response at 3 months. Conventional radiotherapy remained effective with a 50-60% pain relief rate, but only lasting four months.
The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.
Neurologist Soma Sengupta introduces the concept of integrative neuro-oncology, combining conventional treatments with alternative therapies to enhance patient well-being. Her approach prioritizes the unique needs of brain tumor patients and their caregivers, promoting a holistic understanding of medicine.